Cipro (Ciprofloxacin, BAYQ3939)
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cystitis / Pyelonephritis / Cystic Fibrosis / Anthrax
Conditions
Cystitis / Pyelonephritis / Cystic Fibrosis / Anthrax
Trial Timeline
Jul 15, 2016 → Jun 13, 2019
NCT ID
NCT02555059About Cipro (Ciprofloxacin, BAYQ3939)
Cipro (Ciprofloxacin, BAYQ3939) is a pre-clinical stage product being developed by Bayer for Cystitis / Pyelonephritis / Cystic Fibrosis / Anthrax. The current trial status is completed. This product is registered under clinical trial identifier NCT02555059. Target conditions include Cystitis / Pyelonephritis / Cystic Fibrosis / Anthrax.
What happened to similar drugs?
2 of 5 similar drugs in Cystitis / Pyelonephritis / Cystic Fibrosis / Anthrax were approved
Approved (2) Terminated (2) Active (2)
✅Pentosan polysulfate sodium 100 mg + Placebo + Pentosan polysulfate sodium 100 mgJohnson & JohnsonApproved
Hype Score Breakdown
Clinical
3
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02555059 | Pre-clinical | Completed |
| NCT01690559 | Pre-clinical | Completed |
Competing Products
19 competing products in Cystitis / Pyelonephritis / Cystic Fibrosis / Anthrax
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ferumoxytol + Gadobutrol | Lipella Pharmaceuticals | Phase 1 | 19 |
| LP-10 | Lipella Pharmaceuticals | Phase 2 | 25 |
| LP-08 80mg + Normal saline + LP-08 20mg | Lipella Pharmaceuticals | Phase 2 | 25 |
| ASP3652 + Placebo | Astellas Pharma | Phase 2 | 35 |
| Mirabegron + Placebo | Astellas Pharma | Phase 3 | 32 |
| ONO-1110 + Placebo | Ono Pharmaceutical | Phase 2 | 42 |
| Placebo + JNJ-42160443 | Johnson & Johnson | Phase 2 | 27 |
| Pentosan polysulfate sodium 100 mg + Placebo + Pentosan polysulfate sodium 100 mg | Johnson & Johnson | Approved | 35 |
| BOTOX + Placebo for BOTOX | AbbVie | Phase 2 | 35 |
| Rocuronium | Merck | Approved | 43 |
| Cidofovir | Gilead Sciences | Pre-clinical | 18 |
| PD 0299685 at 15mg BID + PD 0299685 at 30mg BID + placebo for PD 0299685 | Pfizer | Phase 2 | 35 |
| Tanezumab + Tanezumab + Tanezumab + Tanezumab | Pfizer | Phase 2 | 27 |
| ERB-041 | Pfizer | Pre-clinical | 18 |
| PF-04383119 + Placebo | Pfizer | Phase 2 | 35 |
| Certolizumab pegol + Placebo | UCB | Phase 3 | 40 |
| moxifloxacin | Bayer | Phase 3 | 37 |
| IW-3300 rectal foam + Placebo | Ironwood Pharmaceuticals | Phase 2 | 21 |
| MN-001 BID + MN-001 + Placebo | MediciNova | Phase 2 | 25 |